Chromatin H3K27me3/H3K4me3 histone marks define gene sets in high-grade serous ovarian cancer that distinguish malignant, tumour-sustaining and chemo-resistant ovarian tumour cells

Oncogene

Volumn 32, Issue 38, 2013, Pages 4586-4592

  Chapman Rothe, N ^a   Curry, E ^a   Zeller, C ^a   Liber, D ^a   Stronach, E ^a   Gabra, H ^a   Ghaem Maghami, S ^a   Brown, R ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

bivalent genes; chemo resistant cells; ChIPseq; ovarian cancer; tumor sustaining cells

Indexed keywords

HISTONE H3; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CANCER STEM CELL; CHROMATIN; EMBRYONIC STEM CELL; EPIGENETICS; GENE EXPRESSION; HUMAN; HUMAN CELL; MARKER GENE; NUCLEOTIDE SEQUENCE; OVARY CANCER; PRIORITY JOURNAL; TRANSCRIPTION INITIATION SITE; TUMOR CELL; TUMOR GROWTH; UTERINE TUBE;

ANTINEOPLASTIC AGENTS; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; EPIGENOMICS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HISTONES; HUMANS; NEOPLASM GRADING; OVARIAN NEOPLASMS;

EID: 84884589668     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.477     Document Type: Article

References (32)

1. Aletti GD, Gallenberg MM, Cliby WA, Jatoi A, Hartmann LC. Current management strategies for ovarian cancer. Mayo Clin Proc 2007; 82: 751-770.
2. Berkenblit A, Cannistra SA. Advances in the management of epithelial ovarian cancer. J Reprod Med 2005; 50: 426-438.
3. Agarwal R, Kaye SB. Ovarian cancer: Strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003; 3: 502-516.
4. Bernstein BE, Mikkelsen TS, Xie X, Kamal M, Huebert DJ, Cuff J et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 2006; 125: 315-326.
5. Ohm JE, McGarvey KM, Yu X, Cheng L, Schuebel KE, Cope L et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet 2007; 39: 237-242.
6. Widschwendter M, Fiegl H, Egle D, Mueller-Holzner E, Spizzo G, Marth C et al. Epigenetic stem cell signature in cancer. Nat Genet 2007; 39: 157-158.
7. Ringrose L, Paro R. Epigenetic regulation of cellular memory by the Polycomb and Trithorax group proteins. Annu Rev Genet 2004; 38: 413-443.
8. Ho JW, Bishop E, Karchenko PV, Negre N, White KP, Park PJ. ChIP-chip versus ChIPseq: Lessons for experimental design and data analysis. BMC Genomics 2011; 12: 134.
9. Rizzo S, Hersey JM, Mellor P, Dai W, Santos-Silva A, Liber D et al. Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol Cancer Ther 2011; 10: 325-335.
10. Hu L, McArthur C, Jaffe RB. Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. Br J Cancer 2010; 102: 1276-1283.
11. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R et al. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. PNAS 2006; 103: 11154-11159.
12. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 2008; 68: 4311-4320.
13. Lee TI, Jenner RG, Boyer LA, Guenther MG, Levine SS, Kumar RM et al. Control of developmental regulators by Polycomb in human embryonic stem cells. Cell 2006; 125: 301-313.
14. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003; 4: 249-264.
15. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-615.
16. Zhao XD, Han X, Chew JL, Liu J, Chiu KP, Choo A et al. Whole-genome mapping of histone H3 Lys4 and 27 trimethylations reveals distinct genomic compartments in human embryonic stem cells. Cell Stem Cell 2007; 1: 286-298.
17. Thomas PD, Kejariwal A, Guo N, Mi H, Campbell MJ, Muruganujan A et al. Applications for protein sequence-function evolution data: MRNA/protein expression analysis and coding SNP scoring tools. Nucleic Acids Res 2006; 34: W645-W650.
18. Schwartz YB, Pirrotta V. Polycomb silencing mechanisms and the management of genomic programmes. Nat Rev Genet 2007; 8: 9-22.
19. Irizarry RA, Wang C, Zhou Y, Speed TP. Gene set enrichment analysis made simple. Stat Methods Med Res 2009; 18: 565-575.
20. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 2008; 14: 5198-5208.
21. Langdon SP, Lawrie SS, Hay FG, Hawkes MM, McDonald A, Hayward IP et al. Characterization and properties of nine human ovarian adenocarcinoma cell lines. Cancer Res 1988; 48: 6166-6172.
22. Stronach EA, Alfraidi A, Rama N, Datler C, Studd JB, Agarwal R et al. HDAC4-Regulated STAT1 activation mediates platinum resistance in ovarian cancer. Cancer Res 2011; 71: 4412-4422.
23. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Molec Biol 2004; 3: 3.
24. Matsumura N, Huang Z, Mori S, Baba T, Fujii S, Konishi I et al. Epigenetic suppression of the TGF-beta pathway revealed by transcriptome profiling in ovarian cancer. Genome Res 2011; 21: 74-82.
25. Meng Q, Xia C, Fang J, Rojanasakul Y, Jiang BH. Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway. Cell Signal 2006; 18: 2262-2271.
26. Zhang HY, Zhang PN, Sun H. Aberration of the PI3K/AKT/mTOR signaling in epithelial ovarian cancer and its implication in cisplatin-based chemotherapy. Eur J Obstet Gynaecol Reprod Biol 2009; 146: 81-86.
27. Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L et al. Regulation of tumor angiogenesis by EZH2. Cancer Cell 2010; 18: 185-197.
28. Zeller C, Dai W, Steele NL, Siddiq A, Walley AJ, Wilhelm-Benartzi CS et al. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling. Oncogene 2012; 31: 4567-4576.
29. Nelson JD, Denisenko O, Bomsztyk K. Protocol for the fast chromatin immunoprecipitation (ChIP) method. Nat Protoc 2006; 1: 179-185.
30. Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol 2009; 10: R25.
31. Zang C, Schones DE, Zeng C, Cui K, Zhao K, Peng W. A clustering approach for identification of enriched domains from histone modification ChIP-Seq data. Bioinformatics 2009; 25: 1952-1958.
32. Wu D, Lim E, Vaillant F, Asselin-Labat M-L, Visvader JE, Smyth GK. ROAST: Rotation gene set tests for complex microarray experiments. Bioinformatics 2010; 26: 2176-2182.